PDP1 and acute myeloid leukemia: Accordingly, our data demonstrated that a combination of PI3K/AKT/mTOR pathway inhibitors regulates the expression of genes involved in glycolysis, the PDH complex, and the TCA cycle and interferes with metabolic reprogramming of AML leukemic cells.